Mostrar el registro sencillo del ítem

Revisiting the Evidence for Dipyridamole in Reducing Restenosis: A Systematic Review and Meta-analysis

dc.rights.licenseopenen_US
dc.contributor.authorSIMARD, Trevor
dc.contributor.authorMOTAZEDIAN, Pouya
dc.contributor.authorDHALIWAL, Shan
dc.contributor.authorDI SANTO, Pietro
dc.contributor.authorJUNG, Richard
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorRAMIREZ, Francisco Daniel
dc.contributor.authorLABINAZ, Alisha
dc.contributor.authorSHORT, Spencer
dc.contributor.authorPARLOW, Simon
dc.contributor.authorJOSEPH, Joanne
dc.contributor.authorRASHEED, Adil
dc.contributor.authorROCKLEY, Mark
dc.contributor.authorMARBACH, Jeffrey
dc.contributor.authorDOMECQ, Marie-Cecile
dc.contributor.authorRUSSO, Juan J.
dc.contributor.authorCHONG, Aun-Yeong
dc.contributor.authorBEANLANDS, Rob S.
dc.contributor.authorHIBBERT, Benjamin
dc.date.accessioned2021-08-24T09:05:35Z
dc.date.available2021-08-24T09:05:35Z
dc.date.issued2021-04-01
dc.identifier.issn1533-4023 (Electronic) 0160-2446 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/110200
dc.description.abstractEnAtherosclerosis remains a leading cause of morbidity and mortality, with revascularization remaining a cornerstone of management. Conventional revascularization modalities remain challenged by target vessel reocclusion-an event driven by mechanical, thrombotic, and proliferative processes. Despite considerable advancements, restenosis remains the focus of ongoing research. Adjunctive agents, including dipyridamole, offer a multitude of effects that may improve vascular homeostasis. We sought to quantify the potential therapeutic impact of dipyridamole on vascular occlusion. We performed a literature search (EMBASE and MEDLINE) examining studies that encompassed 3 areas: (1) one of the designated medical therapies applied in (2) the setting of a vascular intervention with (3) an outcome including vascular occlusion rates and/or quantification of neointimal proliferation/restenosis. The primary outcome was vascular occlusion rates. The secondary outcome was the degree of restenosis by neointimal quantification. Both human and animal studies were included in this translational analysis. There were 6,839 articles screened, from which 73 studies were included, encompassing 16,146 vessels followed up for a mean of 327.3 days (range 7-3650 days). Preclinical studies demonstrate that dipyridamole results in reduced vascular occlusion rates {24.9% vs. 48.8%, risk ratio 0.53 [95% confidence interval (CI) 0.40-0.70], I-2 = 39%, P < 0.00001}, owing to diminished neointimal proliferation [standardized mean differences -1.13 (95% CI -1.74 to -0.53), I-2 = 91%, P = 0.0002]. Clinical studies similarly demonstrated reduced occlusion rates with dipyridamole therapy [23.5% vs. 31.0%, risk ratio 0.77 (95% CI 0.67-0.88), I-2 = 84%, P < 0.0001]. Dipyridamole may improve post-intervention vascular patency and mitigate restenosis. Dedicated studies are warranted to delineate its role as an adjunctive agent after revascularization.
dc.language.isoENen_US
dc.subject.enDipyridamole
dc.subject.enAggrenox
dc.subject.enRestenosis
dc.subject.enISR
dc.subject.enPatency
dc.subject.enOcclusion
dc.title.enRevisiting the Evidence for Dipyridamole in Reducing Restenosis: A Systematic Review and Meta-analysis
dc.typeArticle de revueen_US
dc.identifier.doi10.1097/fjc.0000000000000976en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed33760800en_US
bordeaux.journalJournal of Cardiovascular Pharmacologyen_US
bordeaux.page450-457en_US
bordeaux.volume77en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue4en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamMORPH3Eusen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03324955
hal.version1
hal.date.transferred2021-08-24T09:05:40Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Journal%20of%20Cardiovascular%20Pharmacology&amp;rft.date=2021-04-01&amp;rft.volume=77&amp;rft.issue=4&amp;rft.spage=450-457&amp;rft.epage=450-457&amp;rft.eissn=1533-4023%20(Electronic)%200160-2446%20(Linking)&amp;rft.issn=1533-4023%20(Electronic)%200160-2446%20(Linking)&amp;rft.au=SIMARD,%20Trevor&amp;MOTAZEDIAN,%20Pouya&amp;DHALIWAL,%20Shan&amp;DI%20SANTO,%20Pietro&amp;JUNG,%20Richard&amp;rft.genre=article


Archivos en el ítem

ArchivosTamañoFormatoVer

No hay archivos asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem